The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 13F

FORM 13F INFORMATION TABLE
OMB APPROVAL
OMB Number: 3235-0006
Estimated average burden
hours per response: 23.8
COLUMN 1 COLUMN 2 COLUMN 3 COLUMN 4 COLUMN 5 COLUMN 6 COLUMN 7 COLUMN 8
VALUE SHRS OR SH/ PUT/ INVESTMENT OTHER VOTING AUTHORITY
NAME OF ISSUER TITLE OF CLASS CUSIP (x$1000) PRN AMT PRN CALL DISCRETION MANAGER SOLE SHARED NONE
Akari Therapeutics Plc COM 00972G108 1,846 426,297 SH   SOLE   426,297 0 0
AnaptysBio COM 032724106 28,458 282,550 SH   SOLE   282,550 0 0
ARCA biopharma Inc COM 00211Y100 1,457 1,078,932 SH   SOLE   1,078,932 0 0
Argenx COM 04016X101 40,996 649,665 SH   SOLE   649,665 0 0
Ascendis Pharma A/S COM 04351P101 44,587 1,113,014 SH   SOLE   1,113,014 0 0
AveXis Inc COM 05366U100 114,616 1,035,657 SH   SOLE   1,035,657 0 0
Bellerophon Therapeutics COM 078771102 9,671 4,149,378 SH   SOLE   4,149,378 0 0
BioCryst Pharmaceuticals Inc COM 09058V103 12,187 2,482,119 SH   SOLE   2,482,119 0 0
Biohaven Pharmaceuticals COM G11196105 46,368 1,718,605 SH   SOLE   1,718,605 0 0
Catalyst Biosciences COM 14888D109 3,215 235,676 SH   SOLE   235,676 0 0
DBV Technologies COM F2927N109 20,683 673,617 SH   SOLE   673,617 0 0
Edge Therapeutics Inc COM 279870109 9,137 975,103 SH   SOLE   975,103 0 0
Lipocine Inc COM 53630X104 1,331 386,928 SH   SOLE   386,928 0 0
Obseva SA COM H5861P103 19,411 1,988,843 SH   SOLE   1,988,843 0 0
Ra Pharmaceuticals COM 74933V108 4,629 544,612 SH   SOLE   544,612 0 0
Savara Inc COM 805111101 18,691 1,259,500 SH   SOLE   1,259,500 0 0
Spero Therapeutics Inc COM 84833T103 5,706 485,615 SH   SOLE   485,615 0 0
Zogenix COM 98978L204 34,205 854,057 SH   SOLE   854,057 0 0